Semaglutide Improves Reward-Based Motivation in Patients With Major Depressive Disorder

Major depressive disorder is frequently characterized by profound deficits in reward processing and motivation that often persist despite standard antidepressant therapy. While glucagon-like peptide-1 receptor agonists are established treatments for type 2 diabetes and obesity, evidence suggests these agents also modulate central reward circuits [1, 2]. Clinical interest has expanded to their potential role in treating cognitive dysfunction and metabolic disturbances associated with psychiatric conditions, particularly those exacerbated by antipsychotic medications [3, 4]. Furthermore, bidirectional communication within the microbiota-gut-brain axis (the signaling network between the gastrointestinal tract and the central nervous system) suggests that metabolic hormones regulate complex behaviors and glial functions, which are the activities of non-neuronal cells that maintain brain homeostasis [5]. A randomized clinical trial of 72 participants recently demonstrated that 14 mg of oral semaglutide significantly improved measures of motivation by reducing the perceived cost of effort relative to reward (P =.02), suggesting a potential role for these agents in treating the motivational deficits of clinical depression [6].